Within this framework, NAMs correspond to the low-CSD category and are characterized by a stepwise progression from a benign BRAF V600E-mutated nevus through intermediate lesions harboring TERT, CDKN2A, and SWI/SNF mutations, to in situ and invasive melanoma, with PTEN alterations emerging at later stages [10]. The gene discussed is CDKN2A; the disease is nevus.